Project Grant R01AI181626
Award Date
1/25/24
Completion Date
11/30/28
Dollars Obligated
$781K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Emory University a $1,761,680 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate the safety and therapeutic potential of a novel HIV cure strategy. The proposed treatment combines soluble IL-15/IL-15RA with a TGF-beta pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, with the goal of achieving sustained viral remission in the...
This $1,314,572 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a HIV cure strategy using CD4-mimetic compounds (CD4MCs) in combination with CD4-induced antibodies (CD4I Abs). The key products and services to be delivered under this 5-year award include: Investigating the use of CD4MCs and CD4I Abs at the time of initial antiretroviral therapy...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $558,317 to Cornell University to conduct comprehensive research on the nature of active HIV-1 reservoirs in alveolar macrophages (AMs) of individuals undergoing long-term combination antiretroviral therapy (cART). The research aims to: 1) characterize the proviral landscapes and viral RNA transcripts in AMs of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $500,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on modulating T cell activation to combat HIV persistence. The 5-year project, starting on September 1, 2024, aims to identify and perturb regulatory mechanisms governing antigen-refractory HIV-specific CD8+ T...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $128,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant aims to develop safer and more specific chimeric antigen receptor (CAR) T cell therapies targeting the PD-1 protein expressed on latently HIV-infected T follicular helper cells. This research seeks to enable the elimination of persistent HIV viral reservoirs in the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $734,317 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Albert Einstein College of Medicine to develop and evaluate cell-specific lentiviral vectors (LVs) capable of selectively generating anti-HIV T cells in vivo. The goal is to enable sustained remission of HIV recurrence in the absence of antiretroviral therapy (ART) by providing robust and sustained anti-HIV T cell and antibody...
This $775,391 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research supports research to determine if therapeutic inhibition of the human protein galectin-9 can accelerate clearance of the latent HIV reservoir, resolve HIV-associated inflammation, and prevent viral rebound following antiretroviral therapy (ART) cessation. The award supports a collaborative research effort between Vitalant...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $209,613 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Michigan to conduct research on single-cell multi-omic analysis of cell differentiation in HIV infection. The research project aims to develop a system of differential equations that extends the RNA velocity framework to incorporate epigenomic data, enabling the estimation of chromatin...
This $2,178,522 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is supporting research to develop enhanced chimeric antigen receptor (CAR) T-cell therapies targeting HIV. The overarching goal is to generate a more potent HIV-specific CAR T-cell product capable of effectively killing HIV-infected cells expressing low levels of the viral antigen. To achieve this, the research team is...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,902,820 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of North Carolina at Chapel Hill (UNC-CH) to determine the molecular mechanism of histone decrotonylation underlying HIV latency. The research aims to establish that distinct from histone deacetylation, histone decrotonylation plays a critical role in the establishment of HIV latency, with the ultimate goal of developing...